We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

European Diabetes Diagnostics Market

By HospiMedica staff writers
Posted on 26 Sep 2005
Spurred by new techniques that are making diabetes monitoring easier, the European market for diabetes diagnostics is forecast to grow from the current U.S.$265 million to $362 million by 2011, according to a new report from Frost & Sullivan (Palo Alto, CA, USA), a global consulting company.

At least one-third of diabetics are ignorant of their condition. For instance, up to a million of Europe's population with type 2 diabetes remain undiagnosed, creating an urgent need to improve public awareness of diabetes and to encourage regular monitoring. Furthermore, there is a need for improvement in physician and healthcare professional awareness and education in order to understand the complete benefits of laboratory-based testing and frequency.

As part of a public awareness campaign, patients need to be educated about the availability of novel tests and therapies. Innovative techniques are making diabetes monitoring much easier, and cutting-edge glucose meters that are compact and easy to handle are replacing imprecise traditional urine-based tests. These trends toward smaller size and ease of use represent attempts by manufacturers to improve patient accuracy, with components that require less time and blood to measure glucose.

Point-of-care (POC) testing, with its ability to provide rapid and simple results, offers an easy approach to regular monitoring of the disease and is already the largest market in Europe for diabetes diagnostics. While the levels of POC and laboratory testing will remain steady over the next several years, the use of glycated hemoglobin testing is expected to rise slightly as general practitioner surgeries, outpatient clinics, and small hospital-based laboratories adopt the technology more readily.

Nevertheless, the overall progress made in the diabetes diagnostics arena needs to be strengthened through continual efforts to achieve more patient-friendly screening and treatment, with emphasis on better education and training.




Related Links:
Frost & Sullivan

New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Automated Blood Typing System
IH-500 NEXT
New
PSA Test
Human Semen Rapid Test
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests